Cellceutix CEO, and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug; Company Provides Update on p53 Compounds From Annual ASCO Meeting
June 4, 2012 | In the News,Press Releases
Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug
May 30, 2012 | Press Releases
Cellceutix Files Amended IND With FDA for Its Novel p53 “Guardian Angel” Anti-Cancer Drug
May 21, 2012 | Press Releases
Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent
May 14, 2012 | Press Releases
Cellceutix Novel Anti-Cancer Compound Kevetrin™ Presented at American Association for Cancer Research Annual Meeting
April 4, 2012 | Press Releases
Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma
March 19, 2012 | Press Releases
Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug
March 12, 2012 | Press Releases
Cellceutix ‘Back in the Game’ With cGMP Manufacturing Completed on New Cancer Drug
February 27, 2012 | Press Releases